|
注册号: Registration number: |
ChiCTR1900020789 |
|
最近更新日期: Date of Last Refreshed on: |
2019-01-19 17:22:35 |
|
注册时间: Date of Registration: |
2019-01-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
生酮饮食治疗线粒体病癫痫的多中心临床研究 |
|
Public title: |
Multi-center clinical study for ketogenic diet in the treatment of mitochondrial epilepsy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
生酮饮食治疗线粒体病癫痫的多中心临床研究 |
|
Scientific title: |
Multi-center clinical study for ketogenic diet in the treatment of mitochondrial epilepsy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄丽娟 |
研究负责人: |
孙丹 |
|
Applicant: |
Huang Lijuan |
Study leader: |
Sun Dan |
|
申请注册联系人电话: Applicant telephone: |
+86 15377555886 |
研究负责人电话:
Study leader's |
+86 13971616910 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huanglijuanwh@163.com |
研究负责人电子邮件: Study leader's E-mail: |
Bloveriver@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市江岸区香港路100号 |
研究负责人通讯地址: |
湖北省武汉市江岸区香港路100号 |
|
Applicant address: |
100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China |
Study leader's address: |
100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属武汉儿童医院 |
||
|
Applicant's institution: |
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属武汉儿童医院 |
||
|
Affiliation of the Leader: |
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
武儿医2018006 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属武汉儿童医院(武汉市妇幼保健院) |
||
|
Name of the ethic committee: |
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan Maternal and Child Healthcare Hospital) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-06-25 00:00:00 | ||
|
伦理委员会联系人: |
索庆丽 |
||
|
Contact Name of the ethic committee: |
Suo Qingli |
||
|
伦理委员会联系地址: |
湖北省武汉市江岸区香港路100号 |
||
|
Contact Address of the ethic committee: |
100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属武汉儿童医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市江岸区香港路100号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
(1)生酮饮食治疗线粒体病癫痫的多中心临床研究 FTCSF-2018-05 (2)深圳市捷利康生物科技有限公司 资金支持 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
(2)Multi-center clinical study of ketogenic diet in the treatment of mitochondrial epilepsy FTCSF-2018-05 (2)Funding Support from Shenzhen ZENECA Biotechnology Co., Ltd. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
线粒体病癫痫 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Mitochondrial epilepsy |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机交叉对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cross-over |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
目前虽然从理论机制上和相关文献均显示KD对线粒体癫痫患儿治疗有效且具有安全性,但目前研究大多数停留在小样本和个案报道,国内没有相应报道,故为了进一步证实KD对线粒体癫痫治疗疗效,我们将联合北京儿童医院、深圳儿童医院等多家儿童医院进行多中心研究,对生酮饮食治疗线粒体脑病伴癫痫患儿进行多中心临床观察,总结中国KD治疗线粒体癫痫患儿状况,进一步明确其疗效性,阻止线粒体病恶化,以改善患儿生活质量。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Although the theoretical mechanism and related literatures have shown that KD is effective and safe in the treatment of children with mitochondrial epilepsy, most of the current studies remain in small samples and case reports. There is no corresponding report in China, in order to further confirm KD efficacy on mitochondrial epilepsy, we will combine with Beijing Children's Hospital, Shenzhen Children's Hospital and other children's hospitals for multi-center research to observe the safety and efficacy of ketogenic diet treatment used for mitochondrial epilepsy, sum up the situation of Chinese KD treatment treating children with mitochondrial epilepsy, further clarify its curative effect and prevent the deterioration of mitochondrial disease to improve the life quality of patients. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
(1)患有严重消化、心血管、呼吸、肝脏、泌尿系统或具有生酮饮食禁忌的遗传代谢性疾病(如:ETC缺陷中复合物2~5型、脂肪酸代谢障碍等),以及先天性免疫缺陷病等不适合生酮饮食治疗者; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients with severe digestion, cardiovascular, respiratory, liver, urinary system or contraindications to ketogenic diet (eg, complex type 2-5 in ETC deficiency, fatty acid metabolism disorders, etc.), and congenital immunodeficiency diseases; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-01-01 00:00:00至 To 2020-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-01-01 00:00:00 至 To 2020-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
中心随机原则 项目期间所有入组的患者统一由指定专门人员负责提供随机设计。合作单位有入组患者时,需及时提供给专门负责人,负责人按照随机设计表,给予患者的入组组别和接受治疗的方法。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Central stochastic principle All patients enrolled during the project are uniformly assigned by a designated specialist to provide a random design. When the cooperating unit has enrolled patients, it needs to be promptly provided to the special responsible person. The responsible person give the patient's enrollment |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开公布发表 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Public Published |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质病例报告表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Paper based CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |